We are live on ! Find out more
PM

Prosight Management Portfolio holdings

AUM $610M
1-Year Est. Return 40.86%
This Fund
S&P 500
This Quarter Est. Return
+2.67%
1 Year Est. Return
+40.86%
3 Year Est. Return
+46.17%
5 Year Est. Return
+1.2%
10 Year Est. Return
–
AUM
$342M
AUM Growth
+$131M
Cap. Flow
+$283M
Cap. Flow %
82.7%
Top 10 Hldgs %
60.71%
Holding
50
New
9
Increased
24
Reduced
4
Closed
13

Top Buys

Rank Stock Value
1
PCRX icon
Pacira BioSciences
PCRX
+$32.5M
2
MGTX icon
MeiraGTx Holdings
MGTX
+$16.7M
3
KURA icon
Kura Oncology
KURA
+$15.9M
4
HUM icon
Humana
HUM
+$15.7M
5
NSTG
NanoString Technologies, Inc.
NSTG
+$14.8M

Top Sells

Rank Stock Value
1
PRTA icon
Prothena Corp
PRTA
+$21.1M
2
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$8.84M
3
ARCT icon
Arcturus Therapeutics
ARCT
+$6.11M
4
ALKS icon
Alkermes
ALKS
+$5.11M
5
CUE icon
Cue Biopharma
CUE
+$4.11M

Sector Composition

Rank Sector Weight
1 Healthcare 99.99%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MRVI icon
26
Maravai LifeSciences
MRVI
$997M
$3.91M 1.14%
+314,300
New +$4.24M
IRTC icon
27
iRhythm Holdings
IRTC
$3.59B
$3.76M 1.1%
+36,030
New +$4.33M
CMPX icon
28
Compass Therapeutics
CMPX
$373M
$3.45M 1.01%
1,083,997
+405,697
+60% +$1.27M
NUVB icon
29
Nuvation Bio
NUVB
$2.24B
$1.98M 0.58%
+1,100,000
New +$1.87M
TDOC icon
30
Teladoc Health
TDOC
$1.58B
$1.95M 0.57%
76,900
+31,000
+68% +$780K
AGL icon
31
Agilon Health
AGL
$1.64B
$1.73M 0.51%
+4,000
New +$2.25M
ALDX icon
32
Aldeyra Therapeutics
ALDX
$91.7M
$1.25M 0.37%
149,511
-233,936
-61% -$2.3M
ELUT icon
33
Elutia
ELUT
$41.1M
$766K 0.22%
324,425
+127,982
+65% +$269K
MODV
34
DELISTED
ModivCare
MODV
$724K 0.21%
16,023
+571
+4% +$33.9K
TOI icon
35
The Oncology Institute
TOI
$498M
$251K 0.07%
455,302
+173,400
+62% +$91.7K
TNET icon
36
PUT
TriNet
TNET
$2.84B
$40.1K 0.01%
+1,604,993
New +$146M
ALDX icon
37
CALL
Aldeyra Therapeutics
ALDX
$91.7M
$10K ﹤0.01%
+671,200
New +$6.61M
ARCT icon
38
Arcturus Therapeutics
ARCT
$157M
– –
-255,000
Closed -$6.11M
BBIO icon
39
BridgeBio Pharma
BBIO
$16.5B
– –
-13,000
Closed -$216K
CUE icon
40
Cue Biopharma
CUE
$135M
– –
-38,395
Closed -$4.11M
LKFT
41
CALL
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.82B
– –
-40,000
Closed -$1.55M
INSM icon
42
Insmed
INSM
$23.2B
– –
-26,359
Closed -$449K
JNJ icon
43
Johnson & Johnson
JNJ
$635B
– –
-25,210
Closed -$3.91M
KALV
44
DELISTED
KalVista Pharmaceuticals
KALV
– –
-240,000
Closed -$1.89M
KZR
45
CALL
DELISTED
Kezar Life Sciences
KZR
– –
-20,000
Closed -$626K
LFST icon
46
Lifestance Health
LFST
$4.16B
– –
-9,000
Closed -$66.9K
TSVT
47
DELISTED
2seventy bio
TSVT
– –
-42,537
Closed -$434K
XBI icon
48
State Street SPDR S&P Biotech ETF
XBI
$10.2B
– –
-273
Closed -$20.8K
MORF
49
DELISTED
Morphic Holding, Inc. Common Stock
MORF
– –
-8,464
Closed -$319K
HZNP
50
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
– –
-81,035
Closed -$8.84M
1
2

Similar funds

PL
Pandi LLC Leawood, Kansas $610M AUM 14.97% 1-Year Est. Return
BFC
Blue Fin Capital Warren, Rhode Island $610M AUM 26.46% 1-Year Est. Return
DCM
DGS Capital Management Jersey City, New Jersey $609M AUM 44.78% 1-Year Est. Return
SAM
Strategy Asset Managers Pasadena, California $609M AUM 32.56% 1-Year Est. Return
CBB
Citizens Business Bank Ontario, California $610M AUM 27.86% 1-Year Est. Return
AIG
American International Group New York $609M AUM 23.67% 1-Year Est. Return
FFWA
FRG Family Wealth Advisors Bellevue, Washington $611M AUM 25.92% 1-Year Est. Return
CIP
Convergence Investment Partners Palm Beach Gardens, Florida $611M AUM 61.48% 1-Year Est. Return

Prosight Management's Q2 2023 Portfolio in Review

As of Q2 2023, Prosight Management held 50 positions worth $342M, up 62% from $211M the previous quarter. Its ten largest holdings account for 61% of the portfolio.

Prosight Management deployed $283M of net new capital in Q2 2023, opening 9 new positions and adding to 24 existing holdings. Its largest new stake was Kura Oncology: 1,343,359 shares worth $14.2M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 99% a quarter earlier.

On the sell side, the largest reduction was Prothena Corp, an estimated $21.1M trimmed.

  • Prosight Management's largest Q2 2023 buy was Kura Oncology: 1,343,359 shares worth $14.2M.
  • Prosight Management added most to Pacira BioSciences in Q2 2023, an estimated $32.5M increase.
  • Prosight Management's biggest Q2 2023 reduction was Prothena Corp, cutting an estimated $21.1M.
  • Prosight Management fully exited Horizon Therapeutics Public Limited Company Ordinary Shares in Q2 2023, selling an estimated $8.84M.
  • Prosight Management's ten largest holdings make up 61% of its $342M portfolio in Q2 2023.
  • Prosight Management opened 9 new positions and closed 13 in Q2 2023.
  • Prosight Management's portfolio value rose 62% quarter-over-quarter to $342M.

Based on Prosight Management's 13F filing for Q2 2023, filed 14 Aug 2023.